ストックスクリーナーアプリを入手
34.17
3.20%
-1.13
アフターアワーズ：
34.45
0.28
+0.82%
前日終値:
$35.30
開ける：
$35.41
24時間の取引高:
1.08M
Relative Volume:
0.99
時価総額：
$1.97B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-15.39
EPS:
-2.22
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
-0.96%
1か月 パフォーマンス:
+29.48%
6か月 パフォーマンス:
+39.19%
1年 パフォーマンス:
+0.47%
1日の値動き範囲:
$33.95
$35.41
1週間の範囲:
$33.36
$40.29
52週間の値動き範囲:
$13.22
$40.29
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(650) 457-1978
住所
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
GPCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
34.17 | 2.14B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | Citigroup | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists - TipRanks
Structure Therapeutics Reports Q3 2025 Financial Results - MSN
Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron’s Potential in the Obesity Market - TipRanks
Avago, Google among market cap stock movers on Wednesday By Investing.com - Investing.com South Africa
Avago, Google among market cap stock movers on Wednesday - Investing.com
Structure Therapeutics Inc ADR (GPCR) is looking forward to a strong quarter - Setenews
A look into Viasat, Inc (VSAT)’s deeper side - Setenews
Structure Therapeutics stock hits 52-week high at 37.66 USD By Investing.com - Investing.com Nigeria
Structure Therapeutics stock hits 52-week high at 37.66 USD - Investing.com
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts - Finviz
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Oral Proteins and Peptides Market Know the Scope and Trends - industrytoday.co.uk
Why Structure Therapeutics Shares Are On The Rise - TipRanks
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Nothing is Better Than Structure Therapeutics Inc ADR (GPCR) stock at the moment - Setenews
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), MBX Biosciences, Inc. (MBX) and Lemaitre Vascular (LMAT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Astrana Health (ASTH) and Viatris (VTRS) - The Globe and Mail
Decoding Structure Therapeutics Inc (GPCR): A Strategic SWOT Ins - GuruFocus
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position - TipRanks
Structure Therapeutics : Corporate Presentation (November 2025) - MarketScreener
Entero Therapeutics’ Board Governance Structure Update - TipRanks
[8-K] Structure Therapeutics Inc. Reports Material Event | GPCR SEC FilingForm 8-K - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) on track for 36-week GLP-1 data year-end 2025 - Stock Titan
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - The Globe and Mail
CapEx per share of Structure Therapeutics, Inc. Sponsored ADR – NASDAQ:GPCR - TradingView
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Wall Street analysts’ outlook for Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pier Capital LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.2%Still a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics - TipRanks
What is Structure Therapeutics Inc ADR (GPCR) Stock Return on Shareholders’ Capital? - Setenews
11,000 Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR Acquired by Allianz Asset Management GmbH - MarketBeat
Allianz Asset Management GmbH Has $252,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Allianz Asset Management GmbH Purchases New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - Defense World
Jazz Pharmaceuticals (NASDAQ: JAZZ) names Ted W. Love, M.D., to board Dec 1, 2025 - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now? - NewsBreak: Local News & Alerts
Critical Survey: Alkermes (NASDAQ:ALKS) and Structure Therapeutics (NASDAQ:GPCR) - Defense World
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Kura Oncology (KURA) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN) and ProQR (PRQR) - The Globe and Mail
Pacific Heights Asset Management LLC Acquires New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX) - The Globe and Mail
(PDF) Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery - researchgate.net
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Abbott Laboratories (ABT) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS) - The Globe and Mail
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
1.88%
大文字化:
|
ボリューム (24 時間):